MedTrace Logo

Gemcitabine as a Single Agent in the Maintenance Chemotherapy of Patients With Metastatic Breast Cancer

NCT02188693 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 267

Last updated 2014-07-14

No results posted yet for this study

Summary

The primary purpose of our study is to evaluate whether gemcitabine as a single agent is superior to observation in improving progression-free survival (PFS) in patients with metastatic breast cancer (MBC) who achieved disease control with an initial six cycles of PG as their first-line treatment

Conditions

  • Stage IIIB, IV, Recurrent, and Metastatic Breast Cancer
  • Gemcitabine
  • Maintenance Chemotherapy

Sponsors & Collaborators

Principal Investigators

  • Li Nanlin, Ph.D · Air Force Military Medical University, China

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-07-31
Primary Completion
2017-07-31
Completion
2017-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02188693 on ClinicalTrials.gov